The AP1S1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population with targeted AP1S1 disruption in the HT29 human colorectal adenocarcinoma cell line. As a pooled loss-of-function model, these cells are suited for studying adaptor protein complex 1 (AP-1) function in protein sorting, endosomal trafficking, and lysosomal biogenesis without clonal selection artifacts.
HT29 cells, derived from a primary colorectal adenocarcinoma, exhibit an adherent epithelial morphology. They serve as a principal intestinal epithelial model, widely used in studies of absorption, barrier function, and cancer biology. The cells form polarized monolayers with enterocytic features, making them valuable for investigating polarized trafficking and receptor-mediated endocytosis.
AP1S1 encodes the sigma1A subunit of the heterotetrameric AP-1 complex, which mediates clathrin-dependent sorting of transmembrane proteins between the trans-Golgi network and endosomes. The AP-1 complex, with subunits AP1G1, AP1B1, AP1M1, and sigma1A, recognizes YXX?? motifs on cargoes such as M6PR, LDLR, transferrin receptor, and MHC-I. AP-1 recruitment is regulated by ARF1 and PI4K, while casein kinase II and GAK control clathrin dynamics; TFEB governs lysosomal biogenesis downstream. AP1S1 knockout disrupts this trafficking, causing mislocalization of cargo receptors and impairing lysosomal and endosomal function.
In HT29 intestinal epithelial cells, AP1S1 knockout disrupts polarized sorting of basolateral and apical receptors such as transferrin receptor, LDLR, and MHC-I, affecting iron uptake, cholesterol homeostasis, and immune surveillance. This model directly relates to MEDNIK syndrome (mental retardation, enteropathy, deafness, neuropathy, ichthyosis, keratodermia), an autosomal recessive disorder caused by AP1S1 mutations. Moreover, AP-1?Cdependent endosomal trafficking influences cell adhesion and migration, with implications for colorectal cancer metastasis. These polyclonal knockout cells thus allow dissection of disease-relevant trafficking defects in a colorectal cancer context.
This knockout model supports diverse applications: endosomal trafficking studies via transferrin uptake assays and immunofluorescence for AP-1 localization; quantification of surface receptors (e.g., transferrin receptor, LDLR) by flow cytometry; and lysosomal enzyme activity measurements. Co-immunoprecipitation with AP1G1 or clathrin enables investigation of protein interactions. Cancer cell migration/invasion assays probe the role of AP-1 in metastasis, while drug delivery studies evaluate nanoparticle internalization. These polyclonal knockout cells provide a robust platform for dissecting clathrin-mediated sorting mechanisms and disease modeling. For technical inquiries, please contact Ascent Research.
